Canada Approves Novavax's COVID-19 Vaccine As Booster In Adults

Canada Approves Novavax's COVID-19 Vaccine As Booster In Adults
  • Health Canada has granted expanded approval to Novavax Inc's NVAX Nuvaxovid (COVID-19 Vaccine as a homologous booster in adults aged 18 and older.
  • The expanded authorization was based on data from a Phase 2 trial conducted in South Africa and the Prevent-19 Phase 3 trial conducted in the U.S. and Mexico. 
  • Related: Novavax Posts Unexpected Q3 Loss, But Revenue Surpass Expectations.
  • As part of the trials, a single booster dose of Nuvaxovid was administered to healthy adult participants approximately six to 11 months after their primary series of two doses administered three weeks apart. 
  • The third (booster) dose produced increased immune responses to levels comparable to or exceeding those associated with protection against COVID-19 in Phase 3 clinical trials.
  • In the trials following the booster, local and systemic reactions had a median duration of approximately two days. The incidence of Grade 3 or higher events remained relatively low.
  • Price Action: NVAX shares are down 4.95% at $19.76 on the last check Friday.
  • Photo by Jernej Furman via Flickr

Posted In: BriefsCOVID-19 CoronavirusCOVID-19 VaccineBiotechLarge CapNewsHealth CareSmall CapGeneral